Key result
Female pre-HFpEF patients have ~23% higher effective arterial elastance and cardiovascular stiffness than males.
Why the study?
Understanding sex-related cardiovascular differences in pre-HFpEF could help explain why females are more likely to develop symptomatic HFpEF compared with males.
Observational (n=250)
Females with pre-HFpEF exhibit greater cardiovascular stiffness and vascular resistance compared to males, suggesting sex-specific pathophysiological mechanisms precede symptomatic heart failure.
May reflect sex-specific pre-HFpEF pathways; hypothesis-generating and should not yet change practice.
Aims Understanding sex-related cardiovascular differences in those with pre-HFpEF (asymptomatic with normal ejection fraction, elevated natriuretic peptides and structural or functional heart disease) could help explain why females are more likely to develop symptomatic HFpEF compared with males. This study analyses sex-related cardiovascular differences in pre-HFpEF, including measures of cardiovascular stiffness and vascular resistance derived from cardiac magnetic resonance imaging (CMR) and Doppler echocardiography. Methods and results This post hoc analysis of the PARABLE trial enrolled 250 patients with pre-HFpEF. CMR and Doppler echocardiography were used to estimate baseline markers of cardiovascular stiffness and resistance, including effective arterial elastance (EAE), systemic vascular resistance (SVR), total arterial compliance (TAC), left ventricular end diastolic pressure (LVEDP) and left ventricular end diastolic chamber stiffness index (LVSId). The population median age was 72.0 [IQR 68.0; 77.0] years and 38.4% were female. Both sexes had a similar age, blood pressure, HbA1c, renal function and H2FPEF score. Fewer female participants had a diagnosis of diabetes and coronary artery disease. When adjusted for age, hypertension, diabetes, obesity and vascular disease, female participants had higher pulse pressures (62.1 (SD 15.3) vs. 60.1 (SD 12.5) mmHg, P < 0.001) as well as higher median [IQR] levels of LDL-cholesterol (2.50 [2.10; 3.25] vs. 2.00 [1.60; 2.40] mmol/L, P < 0.001), EAE (1.55 [1.26; 1.84] vs. 1.26 [1.05; 1.51] mmHg/mL/m2, P < 0.001), SVR (1609 [1288; 1887] vs. 1336 [1132; 1734] mmHg/mL/min2, P = 0.001), LVEDP (18.5 [17.2; 20.1] vs. 18.0 [16.9; 19.3] mmHg, P < 0.001) and LVSId (0.28 [0.24; 0.31] vs 0.24 [0.20; 0.29] mmHg/mL/m2, P < 0.001) than males. Females had higher median [IQR] NT-proBNP (176 [95.8; 286] vs. 127 [81.5; 242] pg/mL, P < 0.001) and lower median [IQR] TAC (1.24 [0.99; 1.58] vs. 1.55 [1.18; 1.91] mL/mmHg, P < 0.001) than male participants. Conclusions Markers of elevated cardiovascular stiffness and vascular resistance are seen in female versus male participants with pre-HFpEF, suggesting that sex-related pathophysiological mechanisms are present before symptoms of HF develop.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2025) conducted an observational in pre-HFpEF (n=250). Female sex vs. Male sex was evaluated on Measures of cardiovascular stiffness and vascular resistance. Female patients with pre-HFpEF had higher markers of cardiovascular stiffness and vascular resistance, such as effective arterial elastance (1.55 vs 1.26 mmHg/mL/m2, P<0.001), compared with males.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: